Archive: February 17 2021


Immunotherapy Web Featured Images 116

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immuno...

The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups.

Visit website
Immunotherapy Web Featured Images 115

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for...

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies.

Visit website